A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical and Metabolic Changes in the Prostate Determined by MRI/3D-MRS and Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex (Bicalutamide) Alone or the Combination of Casodex and ZD1839 (Iressa).

Next Previous
Trial Profile

A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical and Metabolic Changes in the Prostate Determined by MRI/3D-MRS and Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex (Bicalutamide) Alone or the Combination of Casodex and ZD1839 (Iressa).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2011

At a glance

  • Drugs Bicalutamide; Gefitinib
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 20 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top